Abstract
The coronavirus disease 2019 (COVID-19) pandemic illustrated the inability of the market to meet the needed production scale and speed of essential medical products. The state should adopt a risk-based approach, allowing for experimentation with various technological solutions such as vaccines and tests, while ramping up their production. The intervention should resolve uncertainty, combine resources, coordinate technological choices, lift barriers to entry, ensure knowledge sharing, and support the value chain. The cost of this strategy is dwarfed by the economic fallout of a pandemic. Universal testing, an overlooked solution, is a key component of an infrastructure against future pandemics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
